Quote Overview

Stock Activity

Open	454.79
Day Low	445.22
Day High	454.79
52 Wk Low	320.01
52 Wk High	457.66
Avg. Volume	1,132,148
Market Cap	117.92 B
Dividend	NA
Beta	0.39

Key Earnings Data

Earnings ESP	0.18%
Most Accurate Est	4.14
Current Qtr Est	4.13
Current Yr Est	17.14
Exp Earnings Date	8/6/24
Prior Year EPS	15.23
Exp EPS Growth (3-5yr) 12.78%
Forward PE	26.67
PEG Ratio	2.09

Medical » Medical - Biomedical and Genetics

Research Reports for VRTX

All Zacks’ Analyst Reports

Premium Research for VRTX

Style Scores D Value B Growth B Momentum C VGM
Zacks Rank	Hold 3
Zacks Industry Rank	Top 35%(89 out of 252)
Zacks Sector Rank	Top 38% (6 out of 16)
Earnings ESP	0.18%
Research Reports for VRTX Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Vertex Pharmaceuticals	VRTX
Basilea Pharmaceutica	BPMUF
AEON Biopharma, Inc.	AEON
ALX Oncology Holdings	ALXO
AN2 Therapeutics	ANTX
Adlai Nortye Ltd. Sponsored ADR	ANL
Aileron Therapeutics	ALRN

See all Medical - Biomedical and Genetics Peers

Zacks News for VRTX

No Record found.

Company Summary

Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).

The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat nearly 75% of the 92,000 people with CF in North America, Europe and Australia. Trikafta/Kaftrio (brand name of Trikafta in EU), Vertex’s triple combination regimen, is approved for the treatment of CF in people aged 2 years and older who have at least one F508del mutation in the United States and for CF patients aged 6 and above in countries outside the United States.

In 2023/early 2024, Vertex received regulatory approvals for its one-shot gene therapy Casgevy for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), in the United States and European Union and some other countries like Great Britain, Bahrain and the Kingdom of Saudi Arabia.

While CF remains the main area of focus, Vertex is also developing treatments for acute and neuropathic pain, APOL1-mediated kidney disease, type I diabetes, myotonic dystrophy type 1, alpha-1 antitrypsin deficiency and autosomal dominant polycystic kidney disease (“ADPKD”).

Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen in 2014 while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA in 2017.

The company recorded total revenues of $9.87 billion in 2023, up 11% year over year. Trikafta/ Kaftrio accounted for more than 90% of the company’s total product revenues and generated $8.94 billion in sales in 2023.